GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate Efalizumab Compared With Cyclosporine As an Immunosuppressant Regimen in De Novo Renal Transplantation
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2008-08-07
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00729768
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Completed
- Conditions
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1287
- Registration Number
- NCT00726661
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 451
- Registration Number
- NCT00719472
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MTRX1011A in Patients With Rheumatoid Arthritis
Phase 1
Terminated
- Conditions
- First Posted Date
- 2008-07-18
- Last Posted Date
- 2012-03-07
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT00718588
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis
- First Posted Date
- 2008-06-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00694980
A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT00680316
A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT00679211
A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT00676715
- Locations
- 🇺🇸
Phoenix Neurological Associates Ltd, Phoenix, Arizona, United States
🇧🇬CCB Medical institute, Ministry of Interior Sofia; CLINIC OF NEUROLOGY, Sofia, Bulgaria
🇺🇸MS Center of Vero Beach, Vero Beach, Florida, United States
A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 314
- Registration Number
- NCT00673920
A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT00671372
© Copyright 2024. All Rights Reserved by MedPath